CMS finalizes a scaled-down GLOBE drug payment model for Medicare Part B
Announced Sept 30, 2026; Federal Register Oct 2; begins Jan 1, 2027
From Briefing for the week of September 30 – October 7, 2026
What changed
CMS finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory Medicare Part B model that benchmarks payment to international prices. Performance runs through March 31, 2032, and the model covers roughly a quarter of beneficiaries. Exclusions include orphan-only drugs, plasma-derived products, and certain cell and gene therapies. Law-firm analysis of the final rule reports projected savings falling from about $11.9 billion in the proposal to about $440 million.
Why it matters
A mandatory international-reference model was the administration's flagship drug-price lever. The final design reaches far fewer drugs and beneficiaries than proposed, so the affordability effect for patients and for Medicare is likely small compared with the headline.
Sources
- CMS press release (primary)
- Federal Register: GLOBE Model (primary)
- Covington analysis (secondary)